David Iben put it well when he stated, ‘Volatility is not a risk we care about. What we care about…
Read More
Spyre Therapeutics Announces Proposed Public Offering
Spyre Therapeutics (Nasdaq: SYRE) announced on Oct 13, 2025 that it has…
Read More
Is Oruka Therapeutics’ (ORKA) Fundraising Spree a Sign of Strategic Flexibility or Underlying Caution?
Oruka Therapeutics has recently filed two major shelf registrations exceeding US$1.25 billion and announced a US$200 million follow-on equity offering…
Read More
Leap Therapeutics Raises $58.9M for Digital Asset Treasury
CAMBRIDGE, Mass., Oct. 9, 2025 /PRNewswire/ — Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focapplyd on developing tarobtained and immuno-oncology therapeutics,…
Read More
Cambridge’s Enhanced Genomics extfinishs funding to €16 million to drive development of therapeutics pipeline
Enhanced Genomics, a British BioTech company innovating 3D multi-omics to rapidly identify high-confidence, genetically validated drug tarreceives for common diseases,…
Read More
Defence Therapeutics Raises $2M in Convertible Debenture Offering
Defence Therapeutics (OTCQB: DTCFF) has successfully completed a non-brokered private placement of…
Read More
Alterity Therapeutics Initiates Trading Halt for Capital Raising
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert…
Read More
Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert…
Read More
London’s CHARM Therapeutics raises €68.5 million financing to tackle treatment-resistant cancers
British BioTech startup CHARM Therapeutics, announces closing of an oversubscribed Series B funding round, raising €68.5 million to advance its…
Read More
Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn
Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn, with…
Read More
